Murat Günaltılı

13PUBLICATIONS
37CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jun 16, 2026
Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study.

|May 27, 2026
Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

|May 06, 2026
Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS).

|May 04, 2026
Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change.

|Apr 14, 2026
Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study.

Süleyman Tuna Yolcu, Murat Günaltılı, Emine Ayaz Yolcu

Pageof 3

Frequent Collaborators

10 joint publications

Özkan Alan

7 joint publications

Seda Jeral Evinç

7 joint publications

Hamza Abbasov

6 joint publications

Murad Guliyev